Abstract

ObjectivesTo develop and validate a general radiomics nomogram capable of identifying EGFR mutation status in non-small cell lung cancer (NSCLC) patients, regardless of patient with either contrast-enhanced CT (CE-CT) or non-contrast-enhanced CT (NE-CT).MethodsA total of 412 NSCLC patients were retrospectively enrolled in this study. Patients’ radiomics features not significantly different between NE-CT and CE-CT were defined as general features, and were further used to construct the general radiomics signature. Fivefold cross-validation was used to select the best machine learning algorithm. Finally, a general radiomics nomogram was developed using general radiomics signature, and clinical and radiological characteristics. Two groups of data collected at different time periods were used as two test sets to access the discrimination and clinical usefulness. Area under the receiver operating characteristic curve (ROC-AUC) was applied to performance evaluation.ResultThe general radiomics signature yielded the highest AUC of 0.756 and 0.739 in the two test sets, respectively. When applying to same type of CT, the performance of general radiomics signature was always similar to or higher than that of models built using only NE-CT or CE-CT features. The general radiomics nomogram combining general radiomics signature, smoking history, emphysema, and ILD achieved higher performance whether applying to NE-CT or CE-CT (test set 1, AUC = 0.833 and 0.842; test set 2, AUC = 0.839 and 0.850).ConclusionsOur work demonstrated that using general features to construct radiomics signature and nomogram could help identify EGFR mutation status of NSCLC patients and expand its scope of clinical application.Key Points• General features were proposed to construct general radiomics signature using different types of CT of different patients at the same time to identify EGFR mutation status of NSCLC patients.• The general radiomics nomogram based on general radiomics signature, and clinical and radiological characteristics could identify EGFR mutation status of patients with NSCLC and outperformed the general radiomics signature.• The general radiomics nomogram had a wider scope of clinical application; no matter which of NE-CT and CE-CT the patient has, its EGFR mutation status could be predicted.

Highlights

  • Considering the growing insight into the molecular mechanisms of lung cancer, the treatment of non-small-cell lung cancer (NSCLC) has shifted its focus to determining oncogenic driver mutation subtypes

  • Most radiomics signatures are based on a single type of medical image, which limits the scope of their use due to uncertain image type accessibility for patients in clinical practice

  • Both our proposed general radiomics signature and nomogram could be directly applied on patient’s noncontrast-enhanced CT (NE-CT) or contrast-enhanced CT (CE-CT), which further expand its scope of clinical application

Read more

Summary

Introduction

Considering the growing insight into the molecular mechanisms of lung cancer, the treatment of non-small-cell lung cancer (NSCLC) has shifted its focus to determining oncogenic driver mutation subtypes. A recent study showed that the patient who received third-generation EGFR-TKI of osimertinib even had a longer overall survival [3]. The testing of EGFR mutation status before treatment is very important. The detection of EGFR mutant status relies on tumor tissue from surgical or tissue biopsy, which is an invasive sampling method. Studies have shown that either noncontrast-enhanced CT (NE-CT) or contrast-enhanced CT (CE-CT) can be used to build radiomics models to predict EGFR mutation status [6,7,8,9]. CE-CT showed superior diagnosis abilities over NE-CT in identifying the type of EGFR mutant [10]. Whether radiomic features extracted from NE-CT and CE-CT can be used together to build EGFR mutation status prediction model remains unknown

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.